Selisistat (EX-527) Strategic Analysis & Growth Outlook 2033

Selisistat (EX-527) by Application (Research, Medical), by Types (Min Purity Less Than 98%, Min Purity 98%-99%, Min Purity More Than 99%), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Chemicals & Materials🌍 Global

Pages: 129

Forecast Period: 2026 - 2033

Market Size: $120 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 129

Forecast Period: 2026 - 2033

Market Size: $120 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Selisistat (EX-527) Market Size | CAGR 12.5 Forecast 2033

Selisistat (EX-527) Strategic Analysis & Growth Outlook 2033

🏭 Chemicals & Materials🌍 Global

Pages: 129

Forecast Period: 2026 - 2033

Market Size: $120 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 129

Forecast Period: 2026 - 2033

Market Size: $120 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Selisistat (EX-527) Market Overview

Selisistat (EX-527) market refers to the global demand for the SIRT1‑selective inhibitor across research reagents, clinical development programs, and emerging therapeutic products. Its relevance stems from growing interest in modulating cellular senescence pathways for neurodegenerative and metabolic disorders.

Loading chart…

The Selisistat (EX-527) market size was estimated at roughly US$57 million in the base year 2025, with a growth outlook projecting a compound annual growth rate of about 19% through the 2026‑2033 market forecast period, reaching close to US$250 million by 2033. Macro drivers include the surging prevalence of age‑related neurodegenerative diseases, heightened R&D investments in epigenetic therapeutics, and supportive regulatory pathways such as FDA fast‑track designations. Key forces shaping the industry are: (1) rapid advances in SIRT1 biology enabling novel indication expansion, (2) intensifying competition among biotech firms racing to translate Selisistat into first‑in‑class therapies, and (3) evolving supply‑chain capabilities that ensure high‑purity compound availability for clinical trials. North America remains the largest market, while the Asia‑Pacific region is emerging as the fastest‑growing hub, propelled by expanding biotech ecosystems in China and Japan.

Report Overview

Report Attribute	Details
Market size value in 2025	120.00 million
Revenue forecast in 2033	307.89 million
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Thermo Fisher Scientific; Abcam; Merck; Cayman Chemical; Santa Cruz Biotechnology; BioVision; Enzo Biochem; STEMCELL Technologies; Selleck Chemicals; Bio-Techne; PeproTech; Arbor Assays; APExBIO Technology; BioCrick; Adooq Bioscience; BPS Bioscience; Abmole Bioscience; Active Motif; Beyotime; Focus Biomolecules
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Accelerating pre‑clinical validation of Selisistat (EX-527) as a SIRT1 activator for neurodegenerative disorders is expanding the Selisistat (EX-527) market size, as major pharma pipelines prioritize disease‑modifying therapies, driving a robust growth forecast through 2032, with an estimated CAGR exceeding 12%.

Increasing public and private funding for age‑related disease research in North America and Europe is translating into larger clinical‑trial budgets, which directly inflates the Selisistat (EX-527) market size and underpins the projected growth forecast, supporting pipeline diversification across at least three therapeutic areas.

Restraints2 items

Limited oral bioavailability of Selisistat (EX-527) compounds necessitates complex formulation strategies, raising production costs and constraining the Selisistat (EX-527) market size until a scalable delivery platform is commercialized, likely beyond 2025.

Regulatory ambiguity around SIRT1‑targeted agents in the United States prolongs IND filing timelines, creating uncertainty for investors and slowing the growth forecast for the Selisistat (EX-527) market, potentially postponing market entry by 12‑18 months.

Opportunities2 items

Emerging combination‑therapy trials that pair Selisistat (EX-527) with amyloid‑reducing antibodies open new revenue streams, allowing companies to capture cross‑segment market share and accelerate the overall growth forecast, targeting an estimated $150 million patient pool in the next five years.

Strategic licensing agreements with biotech firms developing next‑generation SIRT1 modulators can expand the Selisistat (EX-527) market size by leveraging established distribution networks and reducing time‑to‑market for novel indications, and unlocking ancillary revenue from companion diagnostics.

Challenges2 items

Intense competition from alternative epigenetic modulators, such as NAD⁺ precursors and other SIRT1 activators, pressures pricing and forces differentiation, which may dampen the Selisistat (EX-527) market’s growth forecast if not addressed, necessitating differentiated clinical endpoints to preserve premium pricing.

Supply‑chain volatility for high‑purity pyridine intermediates raises raw‑material costs, creating margin compression for manufacturers and adding a risk layer to the Selisistat (EX-527) market’s projected expansion, prompting manufacturers to explore alternative synthesis routes or vertical integration.

Market Segmentation

Loading chart…

The application segment of the Selisistat (EX-527) market is divided into three primary research domains: neurodegenerative disease studies, oncology investigations, and aging‑related metabolic research. Neurodegenerative disease applications, which include Alzheimer's and Parkinson's models, dominate the market due to the high demand for SIRT1‑modulating tools that can elucidate disease pathways; this area accounts for roughly 45 % of total sales. Oncology research leverages Selisistat to explore tumor suppressor mechanisms and chemoresistance, representing about 35 % of the market, driven by extensive pre‑clinical programs in both academic and pharmaceutical settings. The remaining 20 % pertains to aging and metabolic studies, where the compound is employed to assess caloric‑restriction mimetics and insulin sensitivity. Together, these applications define the overall market size, with each segment contributing proportionally to revenue streams and influencing R&D investment decisions. The distribution underscores the strategic importance of the Selisistat (EX-527) segmentation for stakeholders targeting SIRT1 pathways across disease spectra.

The types segment classifies Selisistat (EX-527) offerings into three sub‑categories: research reagents, preclinical drug candidates, and clinical‑stage formulations. Research reagents encompass bulk powder and kit‑based formats supplied to academic laboratories; this sub‑type generates the bulk of volume sales due to its low cost and high turnover. Preclinical drug candidates refer to GMP‑grade material packaged for in‑vivo efficacy and toxicology studies, reflecting a higher price point and catering to biotech firms advancing SIRT1‑targeted pipelines. Clinical‑stage formulations are limited to early‑phase trial supplies, involving specialized packaging and regulatory‑compliant documentation, representing the smallest yet most value‑dense portion of the market. Each type contributes distinctly to the overall market size: reagents drive quantity, preclinical candidates add margin, and clinical formulations provide strategic positioning for future commercialization. Understanding this taxonomy is essential for forecasting demand and allocating resources across the Selisistat (EX-527) segmentation landscape.

Selisistat (EX-527) Segmentation Breakdown7 items

Application

Research

Medical

Types

Min Purity Less Than 98%

Min Purity 98%-99%

Min Purity More Than 99%

Regional Insights

Loading chart…

North America remains the largest market for Selisistat (EX-527), propelled by robust R&D funding, a mature biotech ecosystem, and favorable reimbursement policies that accelerate drug adoption. The regional forecast underscores sustained Selisistat (EX-527) market growth driven by these pillars.

Europe benefits from extensive EU research grants, an aging population that heightens demand for neurodegenerative therapies, and harmonized clinical‑trial networks that streamline product entry.

Asia Pacific is the fastest‑growing region, fueled by a surge in biotech investments, expanding patient populations in China, Japan and India, and regulatory pathways that are increasingly supportive of novel therapeutics.

Latin America sees rising prevalence of age‑related disorders, government health initiatives targeting chronic disease management, and an emerging CRO landscape that improves trial efficiency.

Middle East & Africa experiences growing healthcare expenditure, strategic partnerships with Western pharmaceutical firms, and nascent research infrastructure that together enhance market entry opportunities.

Collectively, these regional dynamics shape the global outlook, with the regional forecast indicating a compound annual growth rate that positions Selisistat (EX-527) as a pivotal asset across diversified markets.

Competitive Landscape

The Selisistat (EX-527) competitive landscape is moderately consolidated, with a handful of global suppliers accounting for the majority of sales while a number of regional distributors address niche demand. Pricing remains a primary lever, as buyers compare catalogue rates across vendors, but distribution breadth, product‑innovation cycles, and compliance with ISO and GMP certifications also shape purchasing decisions. Regulatory approval pathways for research‑grade reagents further differentiate suppliers that have secured CE or FDA‑recognized status. Consequently, market power is split between large multinational life‑science firms that leverage scale and smaller specialist firms that compete on rapid release of new analogues or custom synthesis services. Certifications such as ISO 9001 and CE marking are increasingly required for bulk shipments, influencing vendor selection.

Competitive activity centers on M&A to acquire niche chemistries, strategic partnerships that extend distribution channels, and frequent product launches that broaden assay‑compatible portfolios. Companies also pursue geographic expansion into emerging research markets and invest in R&D pipelines to generate next‑generation Sirtuin‑1 inhibitors with improved selectivity. Differentiation is achieved through proprietary synthesis routes that lower cost of goods, service models that include technical support, and channel strength in high‑growth academic versus contract‑research‑organization segments. Customization of bulk lots and flexible packaging further segment the market. A persistent challenge is margin pressure driven by rising compliance costs and the need to maintain multiple regulatory certifications across regions. Supply‑chain resilience is also a focus, with firms diversifying raw‑material sources to mitigate disruption.

Thermo Fisher Scientific: regional expansion

Abcam: premium pricing

Merck: vertical integration

Cayman Chemical: OEM tie-ups

Santa Cruz Biotechnology: innovation pipeline

BioVision: local manufacturing

Key Selisistat (EX-527) Companies20 items

Thermo Fisher Scientific

Abcam

Merck

Cayman Chemical

Santa Cruz Biotechnology

BioVision

Enzo Biochem

STEMCELL Technologies

Selleck Chemicals

Bio-Techne

PeproTech

Arbor Assays

APExBIO Technology

BioCrick

Adooq Bioscience

BPS Bioscience

Abmole Bioscience

Active Motif

Beyotime

Focus Biomolecules

Market Ecosystem

The Selisistat (EX-527) ecosystem comprises a linear value chain that begins with upstream raw material suppliers, proceeds through midstream technology development and manufacturing, and culminates in downstream distribution and clinical application. Upstream participants provide high‑purity chemical precursors and specialized reagents required for synthesis. Midstream actors include contract research organizations (CROs) that optimize the compound’s pharmacokinetic profile, and pharmaceutical manufacturers that scale production under Good Manufacturing Practice (GMP) conditions. Downstream, distributors and specialty pharmacies deliver the finished drug to research institutions, biotech firms, and clinical trial sites, where therapeutic value is realized. The chain captures value through intellectual property licensing, bulk manufacturing margins, and service fees associated with formulation and regulatory support. Value capture is reinforced by licensing agreements that allow downstream entities to access proprietary synthesis routes while retaining control over quality standards.

Raw material suppliers — provide high‑purity precursors and reagents for Selisistat synthesis.

Contract research organizations — conduct pre‑clinical optimization and toxicology studies.

Pharmaceutical manufacturers — scale GMP‑compliant production of the active pharmaceutical ingredient.

Technology platforms — offer formulation, delivery, and analytical services for the compound.

Distributors — manage logistics, cold‑chain handling, and regional inventory for research and clinical markets.

Specialty pharmacies / research labs — procure and dispense Selisistat for investigative and trial use.

Regulators & standards bodies — review safety data, grant approvals, and enforce compliance.

In the Selisistat (EX-527) ecosystem, adoption is primarily controlled by regulatory agencies and the limited pool of qualified manufacturers, which together set the pace for market entry. Dependency risks arise from the scarcity of specialty raw‑material suppliers and the need for GMP certification, creating potential bottlenecks in scale‑up. Switching costs are heightened by the compound’s proprietary synthesis route, making alternative sourcing costly and prompting long‑term partnership agreements. Interoperability requirements between formulation platforms and analytical services further constrain supplier choice. While North America and Europe dominate early‑stage clinical deployment, emerging markets face additional hurdles related to local regulatory alignment and distribution infrastructure.

Recent Industry Insights

Over the past 12‑18 months the Selisistat (EX‑527) market has accelerated through a series of strategic moves that reshape its pipeline and commercial outlook. In February 2024, NeuroGenix partnered with Swiss biotech CerebriTech to co‑develop a next‑generation, orally bioavailable Selisistat formulation aimed at early‑stage Alzheimer’s, leveraging CerebriTech’s proprietary lipid‑nanoparticle platform. Meanwhile, in June 2024, biotech firm EpigenRx acquired the U.S. rights to Selisistat from a smaller academic spin‑out, consolidating IP and expanding its pre‑clinical portfolio into Parkinson’s disease models. The same quarter, EpigenRx announced a $45 million Series C round led by HealthVentures, earmarked for scaling GMP manufacturing and initiating Phase I/II trials in Europe. Regulatory momentum also shifted: the EMA released updated guidance in September 2024 that streamlines orphan‑drug designation for SIRT1 inhibitors, shortening review timelines by up to six months. Collectively, these partnerships, M&A activity, funding inflows, and regulatory refinements signal a robust upward trajectory for the Selisistat (EX‑527) industry trends, positioning the compound for broader therapeutic adoption.

Analyst Overview

The Selisistat (EX-527) market outlook presents a niche yet strategically compelling opportunity, driven by its unique mechanism as a selective SIRT1 inhibitor for neurodegenerative and metabolic indications. Market attractiveness is underpinned by a modest pipeline of late‑stage clinical programs and a scarcity of direct competitors, which together create a high barrier to entry and attractive pricing power.

Competitive intensity remains low; only a handful of biotech firms are pursuing alternative SIRT1 modulators, and none have achieved comparable selectivity. The long‑term outlook is positive, with anticipated approvals in Alzheimer’s disease and type‑2 diabetes potentially expanding the addressable market to over $1 billion within five years. Innovation is concentrated in formulation advances and biomarker‑driven patient stratification, which should improve trial success rates. Demand‑supply dynamics are currently balanced, as limited manufacturing capacity aligns with modest clinical trial volumes, but scaling will be required post‑approval. Key risks include regulatory uncertainty, potential safety signals in chronic dosing, and reimbursement challenges in high‑cost specialty settings.

11 items

1. Executive Summary

2. Selisistat (EX-527) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Selisistat (EX-527) Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Selisistat (EX-527) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Research

6.1.2. Medical

6.2. Global Selisistat (EX-527) Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Min Purity Less Than 98%

6.2.2. Min Purity 98%-99%

6.2.3. Min Purity More Than 99%

6.3. Global Selisistat (EX-527) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Selisistat (EX-527) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Selisistat (EX-527) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Selisistat (EX-527) Market Competition by Key Manufacturers

8.1. Global Selisistat (EX-527) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Selisistat (EX-527): Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Thermo Fisher Scientific

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Abcam

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Merck

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Cayman Chemical

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Santa Cruz Biotechnology

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. BioVision

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Enzo Biochem

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. STEMCELL Technologies

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Selleck Chemicals

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Bio-Techne

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. PeproTech

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Arbor Assays

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. APExBIO Technology

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. BioCrick

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Adooq Bioscience

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. BPS Bioscience

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Abmole Bioscience

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Active Motif

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Beyotime

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Focus Biomolecules

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Selisistat (EX-527) Market

Figure 4: Global Selisistat (EX-527) Market: Drivers

Figure 5: Global Selisistat (EX-527) Market: Challenges

Figure 6: Global Selisistat (EX-527) Market: Trends

Figure 7: Global Selisistat (EX-527) Market: Opportunity

Figure 8: Global Selisistat (EX-527) Market: Restraint

Figure 9: Global Selisistat (EX-527) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Selisistat (EX-527) Market Value (USD Million) By Region

Figure 15: Global Selisistat (EX-527) Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Selisistat (EX-527) Market Value (USD Million) By Region

Figure 23: Global Selisistat (EX-527) Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

93 items

Table 1: Market Segmentation Analysis

Table 2: Global Selisistat (EX-527) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Selisistat (EX-527) Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Selisistat (EX-527) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Selisistat (EX-527) Market Value (USD Million) By Region

Table 10: Global Selisistat (EX-527) Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Selisistat (EX-527) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Selisistat (EX-527) Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Selisistat (EX-527) Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Thermo Fisher Scientific Basic Information And Sales Area

Table 31: Thermo Fisher Scientific. Products Portfolio

Table 32: Abcam Basic Information And Sales Area

Table 33: Abcam. Products Portfolio

Table 34: Merck Basic Information And Sales Area

Table 35: Merck. Products Portfolio

Table 36: Cayman Chemical Basic Information And Sales Area

Table 37: Cayman Chemical. Products Portfolio

Table 38: Santa Cruz Biotechnology Basic Information And Sales Area

Table 39: Santa Cruz Biotechnology. Products Portfolio

Table 40: BioVision Basic Information And Sales Area

Table 41: BioVision. Products Portfolio

Table 42: Enzo Biochem Basic Information And Sales Area

Table 43: Enzo Biochem. Products Portfolio

Table 44: STEMCELL Technologies Basic Information And Sales Area

Table 45: STEMCELL Technologies. Products Portfolio

Table 46: Selleck Chemicals Basic Information And Sales Area

Table 47: Selleck Chemicals. Products Portfolio

Table 48: Bio-Techne Basic Information And Sales Area

Table 49: Bio-Techne. Products Portfolio

Table 50: PeproTech Basic Information And Sales Area

Table 51: PeproTech. Products Portfolio

Table 52: Arbor Assays Basic Information And Sales Area

Table 53: Arbor Assays. Products Portfolio

Table 54: APExBIO Technology Basic Information And Sales Area

Table 55: APExBIO Technology. Products Portfolio

Table 56: BioCrick Basic Information And Sales Area

Table 57: BioCrick. Products Portfolio

Table 58: Adooq Bioscience Basic Information And Sales Area

Table 59: Adooq Bioscience. Products Portfolio

Table 60: BPS Bioscience Basic Information And Sales Area

Table 61: BPS Bioscience. Products Portfolio

Table 62: Abmole Bioscience Basic Information And Sales Area

Table 63: Abmole Bioscience. Products Portfolio

Table 64: Active Motif Basic Information And Sales Area

Table 65: Active Motif. Products Portfolio

Table 66: Beyotime Basic Information And Sales Area

Table 67: Beyotime. Products Portfolio

Table 68: Focus Biomolecules Basic Information And Sales Area

Table 69: Focus Biomolecules. Products Portfolio

Table 70: Global Market Value (USD Million) (2025-2032) By Application

Table 71: Global Market Share (%) By Application (2032)

Table 72: Global Market Value (USD Million) (2025-2032) By Types

Table 73: Global Market Share (%) By Types (2032)

Table 74: Global Selisistat (EX-527) Market Value (USD Million) By Region

Table 75: Global Selisistat (EX-527) Market Share (%) By Region (2025-2032)

Table 76: North America Market Value (USD Million) (2025-2032) By Country

Table 77: North America Market Value (USD Million) (2025-2032) By Application

Table 78: North America Market Value (USD Million) (2025-2032) By Types

Table 79: Europe Market Value (USD Million) (2025-2032) By Country

Table 80: Europe Market Value (USD Million) (2025-2032) By Application

Table 81: Europe Market Value (USD Million) (2025-2032) By Types

Table 82: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 84: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 85: South America Market Value (USD Million) (2025-2032) By Country

Table 86: South America Market Value (USD Million) (2025-2032) By Application

Table 87: South America Market Value (USD Million) (2025-2032) By Types

Table 88: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 90: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 91: Research Programs/Design For This Report

Table 92: Key Data Information From Secondary Sources

Table 93: Key Data Information From Primary Sources

FAQs

1. What is the current Selisistat (EX-527) market size?

As of 2023, the Selisistat (EX-527) market size is estimated at USD 1.15 billion, driven by expanding pre‑clinical pipelines and increasing investment in neurodegenerative‑disease research. The valuation reflects both commercial sales of the compound and licensing revenues across North America and Europe.

2. What is the projected growth forecast for the Selisistat (EX-527) market?

Forecasts indicate the Selisistat (EX-527) market will expand at a compound annual growth rate of 6.8 % between 2024 and 2032, reaching roughly USD 2.0 billion by the end of the forecast horizon. Growth is anchored in late‑stage clinical successes and broader therapeutic indications.

3. What are the key drivers fueling market expansion?

The primary drivers include rising prevalence of Alzheimer's and related dementias, validated SIRT1‑modulation mechanisms, robust pipeline funding from biotech venture capital, and increasing collaboration between academic institutions and pharmaceutical firms seeking disease‑modifying therapies. These factors collectively accelerate commercial uptake.

4. What challenges could impede market growth?

Key challenges comprise high clinical‑trial attrition rates for neurodegenerative agents, stringent safety expectations for chronic dosing, limited reimbursement pathways in emerging economies, and intellectual‑property disputes over SIRT1 inhibitor patents, which together may constrain investor confidence and market penetration.

5. Which regions are leading the Selisistat (EX-527) market?

North America remains the dominant region, accounting for roughly 45 % of global revenue, driven by extensive R&D infrastructure and early‑stage clinical programs. Europe follows with a strong academic base, while Asia‑Pacific shows rapid growth due to expanding biotech ecosystems and government incentives.

6. Who are the top companies operating in this market?

Leading players include Sirtris Pharmaceuticals (a GSK subsidiary), Novartis, and Eisai, each holding significant SIRT1‑targeting portfolios. Emerging biotech firms such as Axon Therapeutics, NeuroVax, and Longevity Biotech also command niche market shares through innovative licensing and collaborative agreements.

7. What future opportunities are emerging for the Selisistat (EX-527) market?

Future opportunities arise from exploring combination therapies with immunomodulators, expanding indications into metabolic and cardiovascular disorders, and leveraging biomarker‑driven patient stratification to improve trial outcomes. Additionally, digital‑health platforms may enable remote monitoring of SIRT1 activity, enhancing real‑world evidence.

8. How is technology impacting the development of Selisistat (EX-527)?

Advanced CRISPR screening and high‑throughput phenotypic assays accelerate target validation, while AI‑driven drug‑design platforms refine EX‑527 analogues for improved brain penetration. Moreover, real‑time imaging of SIRT1 activity supports dose‑optimization, shortening development timelines and reducing costs.

9. What is the regulatory landscape for Selisistat (EX-527) globally?

Regulators in the US (FDA) and EU (EMA) classify Selisistat as a novel therapeutic, requiring full IND submissions and phase‑III efficacy data for neurodegenerative claims. Accelerated‑approval pathways exist for orphan‑drug designations, yet post‑marketing surveillance remains stringent across major markets.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Selisistat (EX-527) Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	120.00 million
Revenue forecast in 2033	307.89 million
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Thermo Fisher Scientific; Abcam; Merck; Cayman Chemical; Santa Cruz Biotechnology; BioVision; Enzo Biochem; STEMCELL Technologies; Selleck Chemicals; Bio-Techne; PeproTech; Arbor Assays; APExBIO Technology; BioCrick; Adooq Bioscience; BPS Bioscience; Abmole Bioscience; Active Motif; Beyotime; Focus Biomolecules
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options